Skip to main content

Influenza, Human

Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Underlying Medical Conditions
NCT02091908 | PHASE 3 | INTERVENTIONAL

Evaluate the safety, immune response and reactogenicity of aH5N1 vaccination in adult (18 through 60 years of age) and elderly (≥61 years of age) subjects with and without underlying medical conditions.

Trial Information
6 Sites
540 Participants
Recruiting
18 Years to 75 Years

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

, Novartis Investigational Site
Berlin,Germany,10117
, Novartis Investigational Site
Dresden,Germany,01307
, Novartis Investigational Site
Hamburg,Germany,20359
, Novartis Investigational Site
Magdeburg,Germany,39120
, Novartis Investigational Site
Rostock,Germany,18055
, Novartis Investigational Site
Wuerzburg,Germany,97070

Study Eligibility Criteria

Additional Studies

Additional studies can be found at ClinicalTrials.gov